Skip to main content

Gilead's twice-yearly shot cut HIV infections by 96% in trial

The data sets the stage for likely approval of Gilead's Lenacapavir for HIV prevention.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.